<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03478605</url>
  </required_header>
  <id_info>
    <org_study_id>OlaCINV</org_study_id>
    <nct_id>NCT03478605</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea &amp; Vomiting (CINV) Prophylaxis</brief_title>
  <acronym>OlaCINV</acronym>
  <official_title>Phase II Randomized Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea &amp; Vomiting (CINV) Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blokhin's Russian Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blokhin's Russian Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Olanzapine-containing regimens for CINV prophylaxis may provide even better protection than
      aprepitant-containing regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Olanzapine-containing regimens for CINV provide high complete response (CR) rate in patients
      receiving high emetogenic chemotherapy. Olanzapine may be more effective than aprepitant in
      this setting but cheaper. However, there is no strong evidence supporting the advantages of
      olanzapine over aprepitant - and this is the reason why aprepitant is still the standard of
      care. Due to high cost aprepitant can be not affordable in low- and middle income countries;
      this compromises quality of life of cancer patients. On the other hand, recommended
      olanzapine-based regimen includes palonosetron, whose price is quite high as well and
      undesired sedation is a common side effect for olanzapine doses that currently recommended,
      these adverse events precludes wide use of olanzapine in oncology. Development of effective,
      tolerable and affordable regimen for CINV prophylaxis based on low-dose olanzapine and
      short-acting 5-HT3 inhibitors can improve quality of care for many cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase II randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nausea control</measure>
    <time_frame>0-120 hours after chemotherapy</time_frame>
    <description>Complete control of nausea (ie, no nausea) in overall treatment period (0-120 hours after chemotherapy).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate in Overall Treatment Period</measure>
    <time_frame>0-120 hours after chemotherapy</time_frame>
    <description>Complete response rate (ie, no vomiting, no use of rescue medication) in 0-120 hours after chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of undesired sedation</measure>
    <time_frame>0-120 hours after chemotherapy</time_frame>
    <description>Rate of undesired sedation 0-120 hours after chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate in Acute Treatment Period</measure>
    <time_frame>0-24 hours after chemotherapy</time_frame>
    <description>Complete response rate (ie, no vomiting, no use of rescue medication) in 0-24 hours after chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate in Delayed Treatment Period</measure>
    <time_frame>24-120 hours after chemotherapy</time_frame>
    <description>Complete response rate (ie, no vomiting, no use of rescue medication) in 24-120 hours after chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Emesis</condition>
  <condition>Vomiting</condition>
  <condition>Nausea Post Chemotherapy</condition>
  <condition>Nausea</condition>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olanzapine 5 mg/day p.o. d 0-4 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d.; IM or P.O. d 2-4;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aprepitant 125 mg p.o d 1 + 80 mg p.o d 2,3 + ondansetron 16 mg IV d 1 + dexamethasone 12 mg IV d 1, 8 mg b.i.d. IM or P.O. d 2-4;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine 5 mg/day will be administered orally on days 0-4 of chemotherapy cycle (before bedtime)</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant Pill</intervention_name>
    <description>Aprepitant 125 mg orally will be administered on day 1 of chemotherapy cycle; 80 mg - on days 2 and 3.</description>
    <arm_group_label>Aprepitant</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_label>Aprepitant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_label>Aprepitant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. High-emetogenic chemotherapy (HEC) regimen (e.g., cisplatin ≥70 mg/m2 or doxorubicin
             ≥60 mg/m2 or carboplatin AUC≥4). Patients that are prescribed less doses of mentioned
             agents are still allowed if another high-emetogenic drug will be administered (eg,
             doxorubicin plus cisplatin);

          2. Administration of HEC component only in first day of the cycle;

          3. No previous chemotherapy or radiotherapy;

          4. No concomitant quinolone antibiotics administration;

          5. ECOG PS ≤2;

          6. No nausea and vomiting 24 hours before enrollment;

          7. Adequate hepatic and renal function (eg, ALaT, ASaT ≤3 ULN, creatinine clearance ≥50
             ml/minute).

          8. No brain metastases, leptomeningeal carcinomatosis, and chronic diseases such as
             uncontrolled diabetes mellitus and chronic alcohol consumption.

          9. Subject willing to participate in the trial and provided informed consent form.

        Exclusion Criteria:

          1. Previous chemotherapy or radiotherapy;

          2. Moderate- or low- emetogenic chemotherapy;

          3. Multiday administration of HEC agents;

          4. ECOG PS &gt;2;

          5. History of brain metastases, signs of symptoms of bowel obstruction;

          6. Nausea and/or vomiting of any genesis 24 hours before enrollment;

          7. Uncontrolled diabetes mellitus or other metabolic diseases; chronic alcohol
             consumption.

          8. Diseases and conditions interfere with subject ability to swallow the drug and to take
             oral medication;

          9. Concomitant therapy with olanzapine or other antipsychotic drugs; history of mental
             illness;

         10. Concomitant therapy with quinolone antibiotics;

         11. Contraindications for olanzapine or aprepitant administration;

         12. Intraperitoneal or intrapleural administration of HEC drugs;

         13. Inadequate hepatic and/or renal function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexey A Rumyantsev, MD</last_name>
    <phone>+79100022255</phone>
    <email>alexeymma@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>N.N. Blokhin Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey A Rumyantsev, MD</last_name>
      <phone>+79100022255</phone>
      <email>alexeymma@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alexey A Rumyantsev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilya A Pokataev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>olanzapine</keyword>
  <keyword>aprepitant</keyword>
  <keyword>CINV</keyword>
  <keyword>nausea</keyword>
  <keyword>vomiting</keyword>
  <keyword>nausea and vomiting</keyword>
  <keyword>antiemetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

